Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market…
Fourth Quarter Net Revenue of $2.6 Million; Full-Year Net Revenue of $10.0 Million;Active Customer Sites Continue to Climb SOUTH ORANGE,…
Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial SolutionsMORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health®…
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…
Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023NEW YORK, Jan. 11, 2023 (GLOBE…
SAN JOSE, Calif., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (“Eargo” or the “Company”) (Nasdaq: EAR), a medical device…
SweetWater Brewing Company's New Georgia Brown Ale For its winter seasonal lineup, SweetWater is re-releasing Georgia Brown, a southern-style brown…
Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC Full data will be presented at…
Agreement provides access to Arbor’s precision editing capabilitiesCAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies (Arbor) today announced…
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and…